DUK
49
4
AMG
33
-11
EMR
57
7
LUV
45
3
CAT
47
3
COP
36
2
MAR
57
3
SO
48
6
PSA
43
6
APH
53
3
IR
46
3
CHRW
53
2
IPG
43
3
CRM
65
6
HRB
40
3
CNP
59
17
LNC
28
3
IRM
33
5
FCX
44
4
ABBV
40
5
DUK
49
4
AMG
33
-11
EMR
57
7
LUV
45
3
CAT
47
3
COP
36
2
MAR
57
3
SO
48
6
PSA
43
6
APH
53
3
IR
46
3
CHRW
53
2
IPG
43
3
CRM
65
6
HRB
40
3
CNP
59
17
LNC
28
3
IRM
33
5
FCX
44
4
ABBV
40
5
Financhill
Back

Corcept Therapeutics Quote, Financials, Valuation and Earnings

How to Turn the AI Energy Crisis into BIG Profits

And investors who move now into one technology could make a whole lot of money.
Buy
62

CORT
Corcept Therapeutics

Last Price:
$51.46
Seasonality Move:
11.1%

7 Day Trial

ALL ACCESS PASS

$ 7

2025 Gold Forecast: A Perfect Storm for Demand

Discover our Gold Price Outlook for 2025--FREE--here

Corcept Therapeutics Price Quote

$51.46
+0.03 (+0.61%)
(Updated: December 21, 2024 at 5:21 AM ET)

Corcept Therapeutics Key Stats

Buy
62
Corcept Therapeutics (CORT) is a Buy
Day range:
$50.02 - $52.35
52-week range:
$20.84 - $62.22
Dividend yield:
0%
P/E ratio:
54.71
P/S ratio:
9.12
P/B ratio:
8.44%
Volume:
2.4M
Avg. volume:
937.3K
1-year change:
66.55%
Market cap:
$5.4B
Revenue:
$482.4M
EPS:
$1.26

How Much Does Corcept Therapeutics Make?

Data Unavailable

Is Corcept Therapeutics Growing As A Company?

Data Unavailable

Corcept Therapeutics Stock Price Performance

What Is Corcept Therapeutics 52-Week High & Low?

Corcept Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Corcept Therapeutics?

Data Unavailable

Is Corcept Therapeutics Cash Flow Positive?

Data Unavailable

Corcept Therapeutics Return On Invested Capital

Data Unavailable

Corcept Therapeutics Earnings Date & Stock Price

Corcept Therapeutics Competitors

  • Who Are Corcept Therapeutics's Competitors?
    Below is a list of companies who compete with Corcept Therapeutics or are related in some way:
    • ADMA Biologics Inc (ADMA)
    • Alnylam Pharmaceuticals Inc (ALNY)
    • Catalyst Pharmaceuticals Inc (CPRX)
    • Ionis Pharmaceuticals Inc (IONS)
    • Madrigal Pharmaceuticals Inc (MDGL)

Corcept Therapeutics Dividend Yield

Data Unavailable

Corcept Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 46.43% 41.38%
Revenue: 47.69% 6.15%

Analyst Recommendations

Buy Recommendations: 0
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 0.00
Downside from Last Price: -100%

Major Shareholders

Data Unavailable